Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $780.65M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.30
• Revenue Growth: -30.25%
• EPS Growth: -5.92%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -2.81
• Shares Outstanding: 76,235,596
• 10 Day Avg. Volume: 1,320,639
• 30 Day Avg. Volume: 1,142,425
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 18.07
• Price to Cash Flow (P/CF): -5.10
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $30.53
• Price Target Upside: 198.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17

Nurix Therapeutics faces considerable challenges, particularly in financial performance and valuation, due to ongoing profitability issues and weak technical indicators. However, the strong balance sheet and positive corporate developments, such as the strategic board appointment, provide some optimism for potential future growth.

Positive Factors

Cash Position

The company maintains a strong cash position (~$550M) with runway into 1H:27.

Financial Performance

Nurix received $18.5M in collaboration revenue in 1Q:25 and an additional $15M license extension fee from Sanofi after the quarter ended.

Regulatory Approval

NX-5948 received FDA orphan drug designation for Waldensrom macroglobulinemia.

Negative Factors

Clinical Risks

Risks include, but are not limited to: negative clinical proof-of-concept for either NX-2127, NX-5948, NX-1607.

Competition

There is notable competition in the space with ONC's BTK degrader BGB-16673 already advancing in a pivotal Ph 2.

Competitive Landscape

Value creation with bexobrutideg is complicated by the robust competitive landscape and tough development path.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

How the Company Makes Money

Nurix Therapeutics makes money through a combination of partnership revenues, milestone payments, and potential future product sales. The company enters into strategic collaborations with larger pharmaceutical firms, granting them access to its DELigase platform for drug discovery and development in exchange for upfront payments, research funding, and milestone payments based on the achievement of specific development, regulatory, and commercial goals. Additionally, Nurix retains rights to certain programs, which could lead to future revenue from product sales if these therapies successfully reach the market. Partnerships play a significant role in Nurix's revenue model, providing financial resources and shared expertise to advance its therapeutic candidates.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. The company has a strong equity position with minimal leverage, but it struggles with profitability as reflected by negative net profit margins and ongoing cash burn from operations.

Income Statement

Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.

Cash Flow

Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
56.42M	54.55M	76.99M	38.63M	29.75M	17.82M
	Gross Profit
48.18M	54.55M	-112.16M	27.82M	23.67M	-48.67M
	EBIT
-230.67M	-213.03M	-155.06M	-183.87M	-117.89M	-64.98M
	EBITDA
-218.13M	-213.03M	-141.41M	-173.06M	-111.80M	-62.80M
	Net Income Common Stockholders
-208.40M	-193.57M	-143.95M	-166.04M	-117.19M	-43.24M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
549.68M	609.58M	287.91M	309.14M	295.72M	281.15M
	Total Assets
615.04M	669.34M	355.60M	416.76M	476.77M	396.34M
	Total Debt
26.62M	28.30M	30.61M	11.96M	13.04M	0.00
	Net Debt
-49.29M	-81.69M	-24.01M	-52.51M	-67.47M	-119.36M
	Total Liabilities
134.13M	142.35M	155.10M	113.06M	134.47M	106.07M
	Stockholders Equity
480.92M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow		Free Cash Flow
-201.59M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
	Operating Cash Flow
-191.72M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
	Investing Cash Flow
-267.69M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
	Financing Cash Flow
485.52M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.24
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Negative. The current price of 10.24 is below the 20-day moving average (MA) of 10.83, below the 50-day MA of 13.71, and below the 200-day MA of 20.14, indicating a bearish trend. The MACD of -1.23 indicates Negative momentum. The RSI at 39.72 is Neutral, neither overbought nor oversold. The STOCH value of 74.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MLYS	53 Neutral	$866.10M	―	-82.24%	―	―	-106.10%
ARVN	52 Neutral	$591.44M	―	-35.41%	―	-39.92%	7.38%
Sector *	51 Neutral	$5.19B	3.13	-40.94%	2.95%	17.94%	2.00%
NRIX	48 Neutral	$780.65M	―	-64.16%	―	-30.25%	-5.92%
IOVA	48 Neutral	$1.00B	―	-57.48%	―	13698.99%	31.46%
RCUS	48 Neutral	$834.03M	―	-59.77%	―	120.51%	25.37%
NTLA	40 Underperform	$748.43M	―	-54.00%	―	59.55%	3.09%

Nurix Therapeutics Corporate Events

Nurix Therapeutics Appoints Dr. Roy D. Baynes to Board

On March 11, 2025, Nurix Therapeutics appointed Dr. Roy D. Baynes to its board of directors and as a member of the Clinical and Commercialization Committee. Dr. Baynes, who has extensive experience in hematology and oncology, will contribute to advancing Nurix’s pipeline across oncology and autoimmune indications. His appointment is expected to enhance the company’s clinical development and commercialization efforts, particularly in the face of growing resistance to BTK inhibitors.